WallStSmart

The Joint Corp (JYNT)vsEli Lilly and Company (LLY)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 147572% more annual revenue ($86.46B vs $58.55M). LLY leads profitability with a 31.9% profit margin vs 6.5%. LLY appears more attractively valued with a PEG of 1.33. LLY earns a higher WallStSmart Score of 74/100 (B).

JYNT

Hold

49

out of 100

Grade: D+

Growth: 6.0Profit: 5.0Value: 3.0Quality: 6.5
Piotroski: 6/9Altman Z: 0.90

LLY

Strong Buy

74

out of 100

Grade: B

Growth: 9.3Profit: 10.0Value: 5.0Quality: 6.0
Piotroski: 6/9Altman Z: 2.16

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

JYNT3 strengths · Avg: 9.3/10
EPS GrowthGrowth
653.0%10/10

Earnings expanding 653.0% YoY

Return on EquityProfitability
20.9%9/10

Every $100 of equity generates 21 in profit

Debt/EquityHealth
0.139/10

Conservative balance sheet, low leverage

LLY6 strengths · Avg: 9.7/10
Market CapQuality
$1.27T10/10

Mega-cap, among the largest globally

Return on EquityProfitability
68.5%10/10

Every $100 of equity generates 68 in profit

Profit MarginProfitability
31.9%10/10

Keeps 32 of every $100 in revenue as profit

Operating MarginProfitability
51.2%10/10

Strong operational efficiency at 51.2%

Revenue GrowthGrowth
38.6%10/10

Revenue surging 38.6% year-over-year

Free Cash FlowQuality
$8.22B8/10

Generating 8.2B in free cash flow

Areas to Watch

JYNT4 concerns · Avg: 2.8/10
Market CapQuality
$106.22M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
6.5%3/10

6.5% margin — thin

Operating MarginProfitability
3.3%3/10

Operating margin of 3.3%

PEG RatioValuation
8.832/10

Expensive relative to growth rate

LLY3 concerns · Avg: 2.3/10
Debt/EquityHealth
1.233/10

Elevated debt levels

P/E RatioValuation
46.3x2/10

Premium valuation, high expectations priced in

Price/BookValuation
31.7x2/10

Trading at 31.7x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : JYNT

The strongest argument for JYNT centers on EPS Growth, Return on Equity, Debt/Equity. Revenue growth of 14.4% demonstrates continued momentum.

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 51.2%. Revenue growth of 38.6% demonstrates continued momentum.

Bear Case : JYNT

The primary concerns for JYNT are Market Cap, Profit Margin, Operating Margin. A P/E of 53.6x leaves little room for execution misses.

Bear Case : LLY

The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.3x leaves little room for execution misses.

Key Dynamics to Monitor

JYNT profiles as a value stock while LLY is a growth play — different risk/reward profiles.

JYNT carries more volatility with a beta of 1.16 — expect wider price swings.

LLY is growing revenue faster at 38.6% — sustainability is the question.

LLY generates stronger free cash flow (8.2B), providing more financial flexibility.

Bottom Line

LLY scores higher overall (74/100 vs 49/100), backed by strong 31.9% margins and 38.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

The Joint Corp

HEALTHCARE · MEDICAL CARE FACILITIES · USA

The Joint Corp. The company is headquartered in Scottsdale, Arizona.

Visit Website →

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

Want to dig deeper into these stocks?